Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19
- Written by PR Newswire
- GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects.After administration, the patients showed trends of improvement of clinical symptoms, shortening time for negative nucleic acid test, and rapid decline of viral load;
- After GS221 being successfully approved for...